DAVID PARK to Neoplasms
This is a "connection" page, showing publications DAVID PARK has written about Neoplasms.
Connection Strength
0.083
-
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026 Mar; 32(3):992-1001.
Score: 0.083
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.